{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:57:24Z","timestamp":1778543844593,"version":"3.51.4"},"reference-count":47,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,3,23]],"date-time":"2007-03-23T00:00:00Z","timestamp":1174608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The <jats:italic>in vitro<\/jats:italic> efficacies of three new drugs \u2013 clofarabine (CLOF), nelarabine (NEL) and flavopiridol (FP) \u2013 were assessed in a panel of acute lymphoblastic leukaemia (ALL) cell lines. The 50% inhibitory concentration (IC50) for CLOF across all lines was 188\u2010fold lower than that of NEL. B\u2010lineage, but not T\u2010lineage lines, were &gt;7\u2010fold more sensitive to CLOF than cytosine arabinoside (ARAC). NEL IC50 was 25\u2010fold and 113\u2010fold higher than ARAC in T\u2010 and B\u2010lineage, respectively. T\u2010ALL cells were eightfold more sensitive to NEL than B\u2010lineage but there was considerable overlap. FP was more potent <jats:italic>in vitro<\/jats:italic> than glucocorticoids and thiopurines and at doses that recent phase I experience predicts will translate into clinical efficacy. Potential cross\u2010resistance of CLOF, NEL and FP was observed with many front\u2010line ALL therapeutics but not methotrexate or thiopurines. Methotrexate sensitivity was inversely related to that of NEL and FP. Whilst NEL was particularly effective in T\u2010ALL, a subset of patients with B\u2010lineage ALL might also be sensitive. CLOF appeared to be marginally more effective in B\u2010lineage than T\u2010ALL and has a distinct resistance profile that may prove useful in combination with other compounds. FP should be widely effective in ALL if sufficient plasma levels can be achieved clinically.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2007.06527.x","type":"journal-article","created":{"date-parts":[[2007,3,23]],"date-time":"2007-03-23T15:21:12Z","timestamp":1174663272000},"page":"109-116","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["<i>In vitro<\/i> cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia"],"prefix":"10.1111","volume":"137","author":[{"given":"Alex H.","family":"Beesley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misty\u2010Lee","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jette","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renae E.","family":"Weller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron J.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"Firth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanchana U.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas H.","family":"De Klerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula R.","family":"Kees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,23]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"241","article-title":"Pharmacology studies of 1\u2010beta\u2010D\u2010arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug","volume":"49","author":"Avramis V.I.","year":"1989","journal-title":"Cancer Research"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603447"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.426"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.3.12.1278"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2276"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0606"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.5124"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0204"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2002.0244"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21005"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1933"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.03.010"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000245326.65152.af"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2142"},{"key":"e_1_2_6_16_1","first-page":"6335","article-title":"Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias","volume":"9","author":"Gandhi V.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2664"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1933"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2122"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.8554"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1201"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(87)90082-8"},{"key":"e_1_2_6_23_1","first-page":"3015","article-title":"Development of resistance to 1\u2010beta\u2010D\u2010arabinofuranosylcytosine after high\u2010dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines","volume":"49","author":"Kees U.R.","year":"1989","journal-title":"Cancer Research"},{"key":"e_1_2_6_24_1","first-page":"671","article-title":"Gene expression profiles in a panel of childhood leukemia cell lines mirror critical features of the disease","volume":"2","author":"Kees U.R.","year":"2003","journal-title":"Molecular Cancer Therapeutics"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E453"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2006.42.7.985638"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.995"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.15.2711"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.13.1791"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.199"},{"key":"e_1_2_6_31_1","first-page":"3352","article-title":"2\u2010Amino\u20106\u2010methoxypurine arabinoside: an agent for T\u2010cell malignancies","volume":"55","author":"Lambe C.U.","year":"1995","journal-title":"Cancer Research"},{"key":"e_1_2_6_32_1","first-page":"2438","article-title":"Biochemical pharmacology and resistance to 2\u2010chloro\u20102\u2019\u2010arabino\u2010fluoro\u20102\u2019\u2010deoxyadenosine, a novel analogue of cladribine in human leukemic cells","volume":"5","author":"Lotfi K.","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0888-7543(03)00045-4"},{"key":"e_1_2_6_34_1","first-page":"3320","article-title":"Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients","volume":"9","author":"Nakanishi T.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000127332.06439.47"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.2.458"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.03.008"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023001"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1724"},{"key":"e_1_2_6_40_1","first-page":"3100","article-title":"Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase","volume":"62","author":"Rodriguez C.O.","year":"2002","journal-title":"Cancer Research"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0317"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.2217\/14796694.2.4.441"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C404"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2986"},{"key":"e_1_2_6_45_1","first-page":"1590","article-title":"A phase II trial of the cyclin\u2010dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non\u2010small cell lung cancer","volume":"7","author":"Shapiro G.I.","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0527-2"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/15257770008033020"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.01.0660"}],"updated-by":[{"DOI":"10.1111\/j.1365-2141.2011.08813.x","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T00:00:00Z","timestamp":1311811200000}}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2007.06527.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2007.06527.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:02:44Z","timestamp":1697439764000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2007.06527.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,23]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1111\/j.1365-2141.2007.06527.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06527.x","archive":["Portico"],"relation":{"erratum":[{"id-type":"doi","id":"10.1111\/j.1365-2141.2011.08813.x","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,23]]},"assertion":[{"value":"2007-03-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}